Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

Diabetes Care

Volumn 21, Issue 10, 1998, Pages 1726-1731

  Brunelle, Rocco L ^a   Llewelyn, Julie ^a   Anderson Jr , James H ^a,c   Gale, Edwin A M ^b   Koivisto, Veikko A ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d University Hospital   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN LISPRO; NEUTRAL INSULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DIABETES MELLITUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031655347     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.10.1726     Document Type: Article

References (49)

1. Reichard P, Nilsson B-Y, Rosenquist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. American Diabetes Association: Standards for medical care for patients with diabetes mellitus. Diabetes Care 18 (Suppl. 1):8-15, 1995
4. McCrimmon RJ, Frier BM: Hypoglycaemia, the most feared complication of insulin therapy. Diabete Metab 20:503-512, 1994
5. Berger M, Mühlhauser I: Implementation of intensified insulin therapy: a European perspective. Diabet Med 12:210-208, 1995
6. Bott S, Bott U, Berger M, Mühlhauser I: Intensified insulin therapy and the risk of severe hypoglycemia, Diabetologia 40:926-932, 1997
7. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
8. Reichard P, Pihl M, Rosenquist U, Sule J: Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up, Diabetologia 39:1483-1488, 1996
9. Egger M, Smith GD, Stettler C, Diem P: Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 14:919-928, 1997
10. Langan SJ, Deary IJ, Hepbum DA, Frier BM: Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mcllitus. Diabetologia 34:337-344, 1991
11. Howey DC, Bowsher RR, Brunelle R, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
12. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment, Diabetes 46:265-270, 1997
13. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study Diabetes 46:440-443, 1997
14. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L DiMarchi R: Mealtime treatment with insulin analogue improves postprandial hyperglycemia and hypoglycemia in NIDDM patients. Arch Intern Med 157: 1249-1255, 1997
15. Anderson JH Jr, Brunelle R, Koivisto VA, Trautmann ME, Vignati S, DiMarchi R, the Multicenter Insulin Lispro Study Group: Improved mealtime treatment of diabetes mellitus using insulin analogue. Clin Ther 19:62-72, 1997
16. Pfützner A, Küstner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H, Beyer J, on behalf of the German Insulin Lispro/IDDM Study Group: Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol 104:25-30, 1996
17. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, DiVincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti F Bolli GB: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37:713-720, 1994
18. Pampanelli S, Torlone E, Lalli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli G: Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta cell function. Diabetes Care 18:1452-1459, 1995
19. Tuominen JA, Karonen S-L, Melamies L, Bolli G, Koivisto VA: Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue, Diabetologia 38:106-111, 1995
20. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharm Ther 58:459-469, 1995
21. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, DiVincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
22. ter Braak EW, Woodworth JR, Blanchi R, Cerimele B, Erkelens DW, Thijssen JH, Kurtz D: Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin, Diabetes Care 19:1437-1440, 1996
23. Heinemann L, Heise T, Wahl LCH, Trautmann ME, Ampudia J, Starke AAR, Berger M: Prandial glycaemia after a carbohydrate-rich meal in type 1 diabetic patients: using the rapid acting insulin analogue [(LysB28), Pro(B29)] human insulin. Diabet Med 13:625-629, 1996
24. Jacobs MAJM, Keulen ETP, Kanc K, Casteleijn S, Scheffer P, Deville W, Heine RJ: Metabolic efficacy of preprandial administration of Lys(B28),Pro(29) human insulin analog in IDDM patients. Diabetes Care 20:1279-1286, 1997
25. Burge MR, Castillo KR, Schade DS: Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care 20:152-155, 1997
26. Jacobs MA, Salobir P, Popp-Snijders C, Ader H, Heine RJ: Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin lispro) in healthy male volunteers. Diabet Med 14:248-257, 1997
27. Henrichs HR, Unger H, Trautmann ME, Pfützner A: Severe insulin resistance treated with insulin lispro. Lancet 348:1248, 1996
28. Lahtela J, Knip M, Paul R, Antonen J, Salmi J: Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. Diabetes Care 20:71-73, 1997
29. Kumar D: Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 20:1357-1359, 1997
30. Jehle PM, Fussgänger RD, Kunze U, Dolderer M, Warchol W, Koop I: The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab 81:2319-2327, 1996
31. Carg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, Chase HP: Pre-meal insulin analogue insulin lispro vs. Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 13:47-52, 1996
32. Burge MR, Waters DL, Holcombe JH, Shade DS: Prolonged efficacy of short acting insulin lispro in combination with human ultralente in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:920-924, 1997
33. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA: Strategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care 20:1287-1289, 1997
34. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327:248-254, 1992
35. Chalmers TC: Data Analysis for Clinical Medicine: The Quantitative Approach to Patient Care in Gastroenterology. Rome, International University Press, 1988, p. 75-84
36. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. New York, Academic Press, 1985
37. Chalmers TC: Problems induced by meta-analysis. Scat Med 10:971-980, 1991
38. SAS Institute: SAS/STAT User's Guide, Version 6. 4th ed. Vol. 1, Cary, NC, SAS Institute, 1989
39. Holleman F, Schmitt H, Rotttiers R, Rees A, Symanowski S, Anderson JH, the Benelux-U.K. Insulin Lispro Study Group: Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 20:1827-1832, 1997
40. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F: Discrepancies between meta-analyses and subsequent large randomized controlled trials. N Engl J Med 337:536-542, 1997
41. Bailar JC III: The promise and problems of meta-analysis. N Engl J Med 337:559-561, 1997
42. Meta-analysis under scrutiny (Editorial). Lancet 350:675, 1997
43. Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, DiVincenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M, Bottini B, Porcellati F, Scionti L, Santeusanio F, Brunetti P, Bolli GB: Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most neuroendocrine responses to, symptoms of and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 42:1683-1689, 1993
44. Cryer PE: Iatrogenic hypoglycemia in IDDM: consequences, risk factors and prevention, In Diabetes Annual Vol. 7. Marshall SM, Home PD, Alberti KGMM, Krall LP, Eds, Amsterdam, Elsevier, 1993, p. 317-331
45. Wredling RAM, Theorell PGT, Roll HM, Lins PES, Adamson UKC: Psychosocial state of patients with IDDM prone to recurrent episodes of severe hypoglycemia. Diabetes Care 15:518-520, 1992
46. Morris AD, Boyle DIR, McMahon AD, Greene SA, MacDonald TM, Newton RW, for the DARTS/MEMO Collaboration: Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus, Lancet 350:1505-1510, 1997
47. Vignati L, Anderson JH Jr, Iversen PW, for the Multicenter Insulin Lispro Study Group: Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Clin Ther 19:1408-1421, 1997
48. Rowe R, Anderson JH, Gale E: Double blind comparison of insulin lispro and regular insulin in patients on multiple injection regimen (Abstract). Diabetes 45 (Suppl. 2):71A, 1996
49. Holcombe J, Zalani S, Arora V: Comparative study of insulin lispro and regular insulin in 481 adolescents with type 1 diabetes (Abstract). Diabetologia 40 (Suppl. 1):A344, 1997